4.7 Article

Calycosin ameliorates advanced glycation end product-induced neurodegenerative changes in cellular and rat models of diabetes-related Alzheimer?s disease

Related references

Note: Only part of the references are listed.
Article Neurosciences

Islet amyloid polypeptide cross-seeds tau and drives the neurofibrillary pathology in Alzheimer's disease

Guoxin Zhang et al.

Summary: The study shows that IAPP interacts with tau and accelerates the formation of a more toxic strain, playing a crucial role in tau pathology in AD. Injection of IAPP-tau strain and IAPP fibrils can induce more severe tau pathology spreading and cognitive impairments.

MOLECULAR NEURODEGENERATION (2022)

Article Clinical Neurology

Untangling the association of amyloid-beta and tau with synaptic and axonal loss in Alzheimer's disease

Joana B. Pereira et al.

Summary: The study found that in early Alzheimer's disease, presynaptic and postsynaptic markers are elevated and associated with more severe amyloid-beta pathology, memory decline, and changes in the default mode network. In later disease stages, abnormal levels of neurofilament light chain were observed, correlated with more tau pathology and worse global cognition.

BRAIN (2021)

Article Multidisciplinary Sciences

Isoform-selective decrease of glycogen synthase kinase-3-beta (GSK-3 beta) reduces synaptic tau phosphorylation, transcellular spreading, and aggregation

Ana Claudia Amaral et al.

Summary: Partial reduction of GSK-3 beta can decrease pathological tau changes in the brain of AD mice, including hyperphosphorylation and aggregation, reducing tau protein spread between neurons. This suggests GSK-3 beta as a promising therapeutic target for AD and other tauopathies.

ISCIENCE (2021)

Article Biochemistry & Molecular Biology

Inhibition of tau aggregation and associated cytotoxicity on neuron-like cells by calycosin

Zhang Zhenxia et al.

Summary: In vitro study showed that calycosin, a phytoestrogen, exhibited anti-amyloidogenic effects by reducing the fibrillation of tau protein and inhibiting the formation of aggregate species and beta-sheet structures. Cellular assays demonstrated that calycosin mitigated tau amyloid fibril-induced cell mortality, LDH release, ROS level, and expression of certain proteins involved in apoptosis. Overall, calycosin may prevent tau amyloid fibrillation and associated cytotoxicity by influencing the formation of oligomeric and fibrillar aggregates with lower solvent-exposed hydrophobic patches.

INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES (2021)

Article Plant Sciences

Sanweidoukou decoction, a Chinese herbal formula, ameliorates β-amyloid protein-induced neuronal insult via modulating MAPK/NF-κB signaling pathways: Studies in vivo and in vitro

Feng-Mao An et al.

Summary: This study demonstrated that the traditional Chinese medicine DK-3 may improve learning and memory abilities of AD-like rats induced by Aβ25-35, and reduce the production of inflammation-related cytokines through significantly inhibited MAPK and NF-κB signaling pathways in both in vitro and in vivo studies.

JOURNAL OF ETHNOPHARMACOLOGY (2021)

Article Clinical Neurology

Diabetes mellitus contributes to higher cerebrospinal fluid tau levels selectively in Alzheimer's disease patients with the APOE4 genotype

Caterina Motta et al.

Summary: The study reveals a significant dependency of CSF t-tau levels on diabetes mellitus for APOE E4+ AD patients; Using A beta(1-42) and p-tau biomarkers is effective in discriminating between pathological changes in AD patients; Glucose metabolism dysfunction interacts with tau protein and APOE genotype to affect the pathological process.

EUROPEAN JOURNAL OF NEUROLOGY (2021)

Article Biochemistry & Molecular Biology

Upregulated expression of a subset of genes in APP;ob/ob mice: Evidence of an interaction between diabetes-linked obesity and Alzheimer's disease

Mitsuru Shinohara et al.

Summary: Clinical studies have shown a link between obesity, diabetes, and Alzheimer's disease, but the specific mechanisms of their interaction remain unclear. Gene expression analysis in mice models revealed a cluster of genes upregulated in the presence of both obesity/diabetes and AD, which might be controlled by a transcription factor called serum response factor (SRF), suggesting a potential common regulator in the conversion of healthy cells to AD cells.

FASEB BIOADVANCES (2021)

Article Neurosciences

Effect of Advanced Glycation End Products on the Progression of Alzheimer's Disease

Ping-Song Chou et al.

JOURNAL OF ALZHEIMERS DISEASE (2019)

Review Neurosciences

The Association of Tau With Mitochondrial Dysfunction in Alzheimer's Disease

Ying Cheng et al.

FRONTIERS IN NEUROSCIENCE (2018)

Review Biochemistry & Molecular Biology

Type 2 Diabetes Mellitus and Alzheimer's Disease: Role of Insulin Signalling and Therapeutic Implications

Andrea Tumminia et al.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)

Article Biochemistry & Molecular Biology

Calycosin ameliorates diabetes-induced cognitive impairments in rats by reducing oxidative stress via the PI3K/Akt/GSK-3β signaling pathway

Xiang Wang et al.

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2016)

Article Biochemistry & Molecular Biology

Early Growth Response 1 (Egr-1) Is a Transcriptional Activator of β-Secretase 1 (BACE-1) in the Brain

Xike Qin et al.

JOURNAL OF BIOLOGICAL CHEMISTRY (2016)

Review Biochemistry & Molecular Biology

The role of advanced glycation end products in various types of neurodegenerative disease: a therapeutic approach

Parveen Salahuddin et al.

CELLULAR & MOLECULAR BIOLOGY LETTERS (2014)

Article Endocrinology & Metabolism

Relationships Between Diabetes and Cognitive Impairment

Suzanne M. de la Monte

ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA (2014)

Review Nutrition & Dietetics

Dietary Advanced Glycation End Products and Aging

Claudia Luevano-Contreras et al.

NUTRIENTS (2010)